Introduction

EGFR (Epidermal Growth Factor Receptor) is a 170-kDa transmembrane glycoprotein tyrosine kinase (TK) receptor on the cell surface which has interaction with EGF growth factors (Jiang and Li, 1997; Yong et al., 2000). In normal cells, the EGFR activation leads to initiation of several signal transduction pathways such as MAPK (mitogen activated protein kinase) STAST (signal transducer and activator of transcription) proteins, SRC kinase family and AKT protein (Protein Kinase B). This activation is correlated with stimulation of the transcription of genes associated with some cellular processes such as cell survival and division (Testa et al., 2000; Bowman et al., 2001; Krasinskas., 2011; Spano et al., 2011).

EGFR level is related to various human tumors such as head, neck, colon, brain glioblastomas, lung, breast, renal and ovarian (Dassonville et al., 1993; Kunkel et al., 1996; Zhang et al., 1998; Etienne et al., 1999). This suggested that blocking EGFR activation would be a logical target in treatment of different cancers. It has been shown that antisense oligonucleotides against growth factors or proto-oncogenes are able to inhibit human cancer proliferation (Normanno et al., 1996; Witters et al., 1999; Mailik and Roy, 2011; Nourazarian et al., 2012a; 2012b). Antisense oligonucleic acid can bind to specific complementary mRNA and inhibit or decrease protein expression (Witters et al., 1999).

Colorectal cancer is the second leading cause of cancer mortality in the Western Societies and represents the third most common type of cancer in worldwide (Greenlee et al., 2000; Siegel et al., 2012). Metastatic in colorectal cancer has poor response to conservative chemotherapeutics in clinical trials (Prewett et al., 2002). Thus antisense therapy offers one approach to colon cancer treatment. EGFR has high expression in colon cancer, associated with Src activation and multiple signaling pathways such STAT5b Kopetz (2007). Also, there is a crosstalk association between STAT5 signaling and MAPK pathway in colorectal cancer (Mao et al., 1997). We previously demonstrated that the EGFR and c-Src antisense oligonucleotide nanoparticles combination decrease HT29 cell lines proliferation (Nourazarian et al., 2012b). In this report, we have studied the in vitro activity of EGFR with nanoparticles encapsulating antisense related with its dependent downstream genes using human colon cancer (HT29).

Keywords: EGFR - antisense - human colon cancer - nanoparticles

Asian Pacific J Cancer Prev. 14 (1), 495-498
Materials and Methods

Cell culture and oligonucleotide nanoparticles transfection

The human colon cancer cell line HT29 (Pasteur Institute Cell Bank of Iran) was grown as monolayer in 25 cm² flask (Orange Scientific) in RPMI-1640 (Roswell Park Memorial Institute 1640) medium (Gibco, invitrogen) supplemented with 10% fetal bovine serum (FBS) (Gibco, invitrogen), penicillin (100 Unit/ml) (Gibco, invitrogen) and streptomycin (100 µg/ml) (Gibco, invitrogen) and placed in incubator at 37°C and 5%CO₂ in a humidified environment. Antisense oligonucleotide nanoparticles transfected to cells as described previously (Nourazarian et al., 2012a; 2012b). Briefly, FITC-labeled EGFR antisense oligodeoxynucleotide (5'-TTTCTTTTCCTCCAGAGCCCG-3') (Eurofins MWG Operon; Germany) incubated with PAMAM nanoparticles solution (QIAGEN; USA) to form complex. Then the solution was transferred to cell wells and incubated for 5 hours at 37°C, 5%CO₂ in incubator.

MTT assay

To determine the effect of EGFR antisense oligonucleotide nanoparticles on the proliferation of the human colon cancer cells (HT29) MTT assay was performed as described previously (Nourazarian et al., 2012a). Briefly HT29 cells were trypsinized from T-flask and 15,000 viable cells seeded per well in 96-well plate and incubated. After exposure time, the cells were treated with EGFR antisense polymers or polymer and antisense alone for control for 5 hours. Then the media was removed and the cells incubated more for 24, 48 and 72 hours for MTT assay. Each experiment was repeated in triplicate format, and results were expressed as means±SEM.

Cell uptake of the EGFR antisense nanoparticles

To evaluate the cellular FITC-labeled EGFR antisense transfection delivery, fluorescence microscopy (Olympus BX61, Olympus Inc.) was performed. For this aim HT29 cells were incubated with EGFR antisense FITC-labeled encapsulated with PAMAM for 5 hours, then washed with PBS and inspect with florescence microscope. Also we used FACs flow cytometry (BD,USA) to confirm data.

Detection of EGFR antisense nanoparticles effect on the related genes expression

After 48 hours transfection of cells with EGFR nanoparticles, total RNA was extracted by Cinagene Kit based on the manufacturer’s instruction (RNX-Plus Solution, SinaClon, Iran). After purification from DNA contaminations, the quality and RNA concentration were determined by detecting light absorbance at 260 (at the ratio of A260/A280) by nanodrop (NanoDrop- ND-1000). cDNA synthesis kit (Qiagen) was used for the cDNA synthesis. To characterize the EGFR antisense nanoparticles effect on the related genes expression, real-time PCR with iCycler IQ5 Multicolor Real-time PCR Detection System (Bio-Rad, USA) was used. For various mRNA, first-strand cDNA was amplified using STAT5 (F 5’- GCCAAGCATGGGACTCAGTG3’ and R 5’- TGGGTGCGCTTATGTTCTCC3’), P53 (F 5’- ATGTGTGCTGACGTCTGTAGTG-3’ and R 5’- ACCACCTTTTGGCCCTCATT-3’), MAPK1 (F 5’- GGTATGTGTTATGAAAGAG-3’ and R 5’- AGCAGAGCAGCAGATGCG-3’) and EGFR (F 5’-GGAGAAGCTCAGAGACCTGACC-3’ and R 5’- GCTGTGAAGACTGTGTTG-3’). GAPDH 5’AAGCTTCTTCTGTGATGACCAAGC3’ and R 5’TTCTCCTTGTGCTTTG-3’ was used for housekeeping genes. Each experiment was repeated in triplicate format, and results were expressed as means±SEM.

EGFR protein expression detection

Western blot analysis was used to evaluate the amount of EGFR expression in the HT29 cells, after antisense therapy. For this aim, protein lysates was prepared from HT9 cells after 48 hours tranfection as described previously (Nourazarian et al., 2012a; 2012b). For Western blot analysis we performed as Chemiluminescent Immunodetection kit based on the manufacturer’s instruction (Western Breeze; Invitrogen).

Statistical analysis

Statistical analysis was performed using by SPSS™ 16.0 software and ANOVA test was used to compare between groups. Data were expressed as Means±SEM. The results were considered significant in case of P≤0.05.

Results

HT29 cell proliferation

MTT assay was performed to measure the effect of EGFR antisense encapsulating with PAMAM on the human colon cancer (HT29) cells proliferation. As Figure 1 shows, after 48 hours EGFR antisense nanoparticles have most effective rather than control groups on cell growth inhibition (P<0.05). However, antisense or PAMAM nanoparticles alone don’t have significant effect on cancer cell lines proliferation (P>0.05).

All the data was compared with control groups

Figure 1. MTT assay was Performed the Effect of EGFR Antisense Oligonucleotides Encapsulated with PAMAM on the HT29 after 48 Hours Treatment

Figure 2. HT29 Cells Treatment with EGFR Antisense FITC-labeled Encapsulated with PAMAM. Light microscopy (left) and fluorescent microscopy image (right)
EGFR Antisense Decrease of EGFR, MAPK1 and STAT5 in Human Colon Cancer Cells

EGFR antisense decrease of EGFR, MAPK1 and STAT5 in human colon cancer cells through ANOVA tests. Note: significantly different from transfected cells and controls (P<0.05)*. Data are represented Mean±SEM. The experiments were repeated as triplicate. Abbreviations: EGFR only, EGFR antisense oligonucleotide without PAMAM; POL, PAMAM nanoparticles, EGFR Poly, complex of antisense oligonucleotide with PAMAM. AS:Sc Scrambled antisense oligonucleotide.

Intercellular delivery of EGFR encapsulated with PAMAM

Microscopic fluorescence results specified EGFR antisense encapsulated FITC-labeled successfully nanoparticles uptake to HT29 cells (Figure 2) also our data shows the complex entered more than 78% cells.

EGFR antisense nanoparticles effects on the related genes expression

We studied the level expression of EGFR and EGFR downstream genes (MAPK1 and STAT5), after antisense therapy on human colon cancer cell lines. The real time PCR results indicate that EGFR antisense encapsulated with PAMAM nanoparticles significantly down-regulated the level of MAPK, EGFR and STAT5 expression in HT29 cell lines (P<0.05) comparing with controls (Figure 3).

EGFR protein expression was down regulated

The western blot analyses data show that the level protein expression of EGFR was significantly decreased via EGFR antisense encapsulated with PAMAM treatment compare with housekeeping gene’s protein expression as control group (P<0.05) (Figure 4).

Discussion

The role of EGFR in colon cancer growth and progression has been described in several studies (Kopetz, 2007). Previous studies have been shown that down-regulation of EGFR expression in human cancer cells decrease via EGFR antisense (Rajagopal et al., 1995; Rubin et al., 1997).

We recently established that the EGFR antisense oligonucleotide encapsulated with PAMAM nanoparticles could reduce human colon cancer cell line (HT29) proliferation and effects on signaling pathway (Nourazarian et al., 2012b). In this study, we have demonstrated that the expression of EGFR, MAPK1 and STAT5 can be significantly reduced in human HT-29 colon cancer cells through EGFR antisense oligonucleotides inhibition. As antisense oligonucleotides have anionic charge and unable to pass into the cells, thus delivery systems should be employed for antisense transfection. For this aim we used polymidoamin polymers, because they are highly effective cationic delivery vehicles and can form PAMAM-antisense complex by electrostatic interaction, as well as they transfer the antisense into nucleus of target cells and have ability to protect the antisense from digestion in cytoplasm (Eichmanet al., 2000; Baker et al., 2004; Orava et al., 2010; Wang et al., 2010).

To determine whether EGFR antisense can decrease the HT-29 colon cancer cell line proliferation, we used cell viability assay. The results of MTT assay showed that PAMAM nanoparticle encapsulating EGFR antisense has significantly decreased the growth of HT29 human colon cancer cells. It confirms the studies which showed that EGFR involves in various downstream signaling pathways such as MAPK1 and STAT5 (Xiong et al., 2009; Park et al., 2011). The roles of STAT genes have been identified in many cancers (Xiong et al., 2009). In addition, EGFR and STAT5 have important role in the survival of cancer cells. Moreover, STAT5b has a role in colon cancer progression, migration, invasion, proliferation, cell cycling and gene expression (Xiong et al., 2009). There are several mechanisms that STAT5 can mediate intracellular EGFR signaling by direct activation of STATs by EGFR binding or indirect activation of STATs via Src-mediated EGFR signaling (Kelly et al., 2007).

Our real time PCR results demonstrated that expression of STAT5b gene has decreased following EGFR inhibition through EGFR reduction by antisense encapsulated nanoparticles. Our results demonstrated PAMAM nanoparticle encapsulating EGFR antisense had more than 40-50% inhibition effects on the EGFR, MAPK1 and STAT5 expression.

The MAPK pathways are downstream of many growth factor receptors, including epidermal growth factor. Over expression of this receptor are detected in colorectal cancer (Fang and Richardson, 2005). The important role of this pathway in cell cycle regulation and colon cancer development has been determined (Chapnick et al., 2011).
EGFR inhibition causes reduction of MAPK expression that is specified in other investigation (Kumar et al., 2010). Our results showed a significant decrease in the amount of MAPK1 gene expression after real time PCR trail.

PAMAM nanoparticles alone have increaseable effects on the above genes expression that suggested PAMAM nanoparticles have an unexpected effect which needs more investigation (Nakhliand et al., 2010).

We suggest that further studies should attempt to colon cancer antisense therapy in vivo experiments on laboratory animals to investigate the efficacy of antisense therapy in biological environments. That this time, we will approach to clinical trials.

Acknowledgements

This work was supported by office of Vice Chancellor for research of Kerman University of Medical Sciences and Research Center for Pharmaceutical Nanotechnology of Tabriz University of Medical Sciences.

References

Bielinska AU, Baker JR, Kukowska-Latallo JF (2004). Dendrimer-mediated cell transfection in vitro. Methods Mol Biol, 245, 67-82.

Bowman T, Garcia R, Turkson J, Jove R (2000). STATs in oncogenesis. Oncogene, 19, 2474-88.

Chapnick D, Warner L, Bernet J, RAO T, Liu X (2011). The TGFBeta and MAPK pathways in cancer progression. Cell and Biosci, 1, 42.

Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR (2000). The use of PAMAM Dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technolo, 3, 232-45.

Etienne MC, Pivot X, Formento JL, et al (1999). A multifactorial approach including tumoural epitheral growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer, 79, 1864-9.

Fang JY, Richardson BC (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol, 6, 322-7.

Francoeur M, Etienne-Grimaldi MC, Formento JL, et al (2006). EGFR in colorectal cancer: more than a simple receptor. Ann Oncol, 17, 962-7.

Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics. CA Cancer J Clin, 50, 7-30.

Krasinskas AM (2011). EGFR Signaling in Colorectal Carcinoma. Patholog Res Int, 14, 932.

Kopetz S (2007). Targeting SRC and epitheral growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Prev, 1, 37-41.

Kumar R, Srivinasan S, Pahari P, Rohr J, Damodaran C (2010). Activating stress-activated protein kinase-mediated cell death and inhibiting epitheral growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther, 9, 2488-96.

Kunkel MW, Hoek KE, Howard CT, et al (1996). Inhibition of the epitheral growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs, 13, 295-302.

Malik R, Roy I (2011). Making sense of therapeutics using antisense technology. Expres Opin Drug Discov, 6, 507-26.

Mao W, Irby R, Coppola, D, et al (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene, 15, 3083-90.

Nakhlband A, Barar J, Bidmehdkpoor A, Heidari HR, Omidi Y (2010). Bioimportacts of anti epitheral growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol, 6, 360-9.

Normanno N, Bianco C, Damiano V, et al (1996). Growth inhibition of human colon carcinoma cells by combinations of antiepitheral growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res, 2, 601-9.

Nourazararian AR, Pasheei-Asl R, Omidi Y, Najar AG (2012). C-Src antisense complex with PAMAM dendrimers decreased c-Src expression and EGFR-dependent downstream genes in human HT-29 colon cancer cell line. Asian Pac J Cancer Prev, 13, 2235-40.

Nourazararian AR, Najar AG, Faraginia S, et al (2012). EGFR and c-Src Antisense Oligodeoxynucleotides Encapsulated with PAMAM Dendrimers Inhibit HT-29 Colon Cancer Cell Proliferation. Asian Pac J Cancer Prev, 13, 4751-6.

Orava EW, Ciemil N, Gariepy J (2010). Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta, 1798, 2190-200.

Park S, Jung HH, Park YH, Ahn JS, Im YH (2011). ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun, 407, 680-686.

Prewett MC, Hooper AT, Bassi R, et al (2002). Enhanced antitumor activity of anti-epitheral growth factor receptor monoclonal antibody JMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res, 8, 994-1003.

Quesnelle KM, Boehm AL, Grandis JR (2007). STAT-mediated EGFR signaling in cancer. J Cell Biochem, 102, 311-9.

Rajagopal S, Huang S, Moskal TL, et al (1995). Epidermal growth factor expression in humancol and colon carcinomas: anti-sense epitheral growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. Int J Cancer, 62, 661-7.

Rubin GJ, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ (1997). Inhibition of epitheral growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene, 15, 409-6.

Sano JP, Fagard R, Soria JC, et al (2005). Epidermal growth factor receptor signaling in colorectal cancer preclinical data and therapeutic perspectives. Annals of Oncol, 16, 189-94.

Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.

Testa JR, Bellacosa A (2001). AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 98, 10983-5.

Wang P, Zhao, Wang, et al (2010). Generation 4 polyamidoamine dendrimers is a novel candidate of nanocarrier for gene delivery agents in breast cancer treatment. Cancer Lett, 298, 34-49.

Witters L, Kumar R, Mandal M, et al (1999). Antisense oligonucleotides to the epitheral growth factor receptor. Breast Cancer Res and Treatment, 53, 41-50.

Xiong H, Su WY, Liang QC, et al (2009). Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest, 89, 717-25.

Yong H, Jun Z, Jin SW, Ke FD (2000). Inhibitory effects of EGFR antisense oligodeoxynucleotide in human colorectal cancer cell line. World J Gastroentero, 6, 747-9.

Zhang X, Geng M, Wang YJ, Cao YC (1998). Expression of epitheral growth factor receptor and proliferating cell nuclear antigen in esophagel carcinoma and pre-cancerous lesions. Huaen XiaoHua Zazhi, 6, 229-30.